Investment Rating - The investment rating for the company is "Accumulate" with a target price of 166.67 CNY, while the current price is 122.38 CNY [5][11]. Core Insights - The company's performance is under pressure due to intensified industry competition affecting its main products, alongside rigid costs leading to profit constraints. In 2025, AestheFill contributed 200 million CNY in revenue, and attention is on the subsequent performance and sales progress of botulinum products [2][11]. - Revenue, net profit attributable to the parent company, and net profit excluding non-recurring gains and losses for 2025 are projected to be 2.453 billion CNY, 1.291 billion CNY, and 1.099 billion CNY, respectively, reflecting year-on-year declines of 18.94%, 34.05%, and 41.30% [11]. - The company is expected to face a decline in revenue and profit margins in the short term, but there is potential for recovery driven by new product launches and international expansion strategies [11]. Financial Summary - Total revenue for 2024 is 3.026 billion CNY, projected to drop to 2.453 billion CNY in 2025, with a subsequent recovery to 2.753 billion CNY in 2026 [4][12]. - Net profit attributable to the parent company is expected to decrease from 1.958 billion CNY in 2024 to 1.291 billion CNY in 2025, with a gradual increase to 1.441 billion CNY in 2026 [4][12]. - The company's gross margin for 2025 is projected at 92.70%, down 1.94 percentage points year-on-year, influenced by product mix changes and increased competition [11]. Product Performance - Revenue from solution and gel products is expected to decline by 27% each in 2025, while the newly acquired AestheFill is anticipated to contribute 208 million CNY in revenue [11]. - The company has received approval for its botulinum product, which is expected to enhance its product matrix and potentially mark a turning point for growth [11]. Market Position and Strategy - The company is positioned as a leading player in the upstream market for aesthetic injection products, focusing on channel development and new methodologies for product launches [11]. - The company is actively pursuing internationalization through acquisitions, such as the integration of REGEN, to expand its global footprint and product offerings [11].

Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company is experiencing a transitional period in its product matrix, leading to a decline in performance. Revenue for 2025 is projected at 2.45 billion, down 19% year-on-year, with net profit expected to be 1.29 billion, a decrease of 34% [1][4] - The company is focusing on new product launches and international expansion as key growth drivers, particularly with the upcoming release of new products such as botulinum toxin and minoxidil, alongside the integration of acquired products from the Korean company Regen [4][5] Financial Performance - For 2025, the gross margin, net margin, and adjusted net margin are projected to be 92.7%, 53.1%, and 44.8%, respectively, reflecting declines of 1.9 percentage points, 11.6 percentage points, and 17.1 percentage points year-on-year [2] - The sales expenses have significantly increased due to personnel expansion and higher marketing costs, impacting overall profitability [2] - Revenue breakdown shows that solution and gel products are still in an adjustment phase, with both categories experiencing declines in revenue and sales volume [3] Future Projections - Revenue is expected to recover to 2.91 billion in 2026, with a growth rate of 18.6%, and further increase to 3.54 billion by 2028, with growth rates of 10.5% and 10.3% in subsequent years [4][5] - Net profit is projected to reach 1.47 billion in 2026, with a year-on-year growth of 13.4%, and continue to grow to 1.83 billion by 2028 [5] Market Position - The company is actively expanding its global sales network and has received regulatory approvals for its products in multiple countries, indicating a strong commitment to international market penetration [4]

Investment Rating - The investment rating for the company is "Buy" [3][12]. Core Insights - The company is experiencing a phase of performance pressure, with a focus on both internal growth and external acquisitions to build long-term growth momentum [1][9]. - In 2025, the company reported a revenue of 2.453 billion yuan, a year-on-year decrease of 18.94%, and a net profit attributable to shareholders of 1.291 billion yuan, down 34.05% year-on-year [8][10]. - The company is expanding its product matrix and therapeutic areas, with new product launches and acquisitions aimed at enhancing its competitive edge and international presence [9]. Financial Performance Summary - Revenue projections for the company are as follows: 2024A: 3.026 billion yuan, 2025A: 2.453 billion yuan, 2026E: 2.793 billion yuan, 2027E: 3.084 billion yuan, 2028E: 3.389 billion yuan [2][10]. - The net profit attributable to shareholders is projected to be: 2024A: 1.958 billion yuan, 2025A: 1.291 billion yuan, 2026E: 1.453 billion yuan, 2027E: 1.618 billion yuan, 2028E: 1.802 billion yuan [2][10]. - The earnings per share (EPS) are expected to be: 2024A: 6.47 yuan, 2025A: 4.27 yuan, 2026E: 4.80 yuan, 2027E: 5.34 yuan, 2028E: 5.96 yuan [2][10]. - The price-to-earnings (P/E) ratio is projected to be: 2024A: 18.94, 2025A: 28.72, 2026E: 25.52, 2027E: 22.96, 2028E: 20.58 [2][10]. Operational Analysis - The revenue breakdown for 2025 shows that solution injection products generated 1.265 billion yuan (down 27.48%), gel injection products 890 million yuan (down 26.82%), and freeze-dried powder products 208 million yuan [8]. - The gross margin for the company in 2025 was 92.7%, a decrease of 1.94 percentage points year-on-year [8]. - The company is increasing its investment in sales and R&D, with expense ratios for sales, management, and R&D rising to 15.77%, 7.44%, and 14.67% respectively [8]. Future Outlook - The company is focusing on both internal product development and external acquisitions to drive growth, with new product launches and the acquisition of REGEN to enhance its international market presence [9]. - The company is expected to continue expanding its product offerings and therapeutic areas, which will provide new growth drivers in the medium to long term [9].

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company is experiencing a transitional period in its product matrix, leading to a temporary decline in performance. Revenue for 2025 is projected at 2.45 billion, down 19% year-on-year, with net profit expected to be 1.29 billion, a decrease of 34% [1][4] - The company is focusing on the launch of new products and expanding its overseas market presence as key growth drivers. Notable upcoming products include the Zhenai Su Fei Tong Yan injection and Minoxidil, which have received regulatory approval [4][5] Financial Performance - Revenue and profit metrics for 2025 indicate significant declines, with a projected revenue of 2.45 billion and a net profit of 1.29 billion, reflecting year-on-year decreases of 19% and 34%, respectively [1][5] - The gross margin for 2025 is expected to be 92.7%, down 1.9 percentage points year-on-year, while the net profit margin is projected at 53.1%, a decline of 11.6 percentage points [2][5] - Sales expenses have increased significantly due to personnel expansion and marketing costs, impacting overall profitability [2][3] Product Segmentation - The company's solution and gel products are currently in an adjustment phase, with revenues for 2025 expected to be 1.265 billion and 890 million, both down 27% year-on-year. The average selling price (ASP) for these products has also decreased [3] - The freeze-dried powder segment, bolstered by the acquisition of Korean Regen, is expected to contribute 210 million in revenue for 2025 [3] Future Projections - Revenue forecasts for 2026 to 2028 are optimistic, with expected revenues of 2.91 billion, 3.22 billion, and 3.55 billion, representing year-on-year growth rates of 18.6%, 10.5%, and 10.3%, respectively [4][5] - Net profit projections for the same period are 1.47 billion, 1.62 billion, and 1.83 billion, with corresponding growth rates of 13.4%, 10.9%, and 12.5% [4][5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding 15% compared to the CSI 300 index [3][12]. Core Insights - The company experienced a significant decline in performance in 2025, with revenue of 2.453 billion yuan, down 18.94% year-on-year, and a net profit of 1.291 billion yuan, down 34.05% year-on-year [8][9]. - The revenue decline is attributed to macroeconomic pressures and intensified industry competition, particularly affecting core products [8]. - The company is focusing on both organic growth and external acquisitions to drive long-term growth, with new product launches and strategic acquisitions enhancing its market position [9]. Financial Performance Summary - Revenue projections for the upcoming years are as follows: 2024A: 3.026 billion yuan, 2025A: 2.453 billion yuan, 2026E: 2.793 billion yuan, 2027E: 3.084 billion yuan, and 2028E: 3.389 billion yuan [2]. - The net profit forecasts are: 2024A: 1.958 billion yuan, 2025A: 1.291 billion yuan, 2026E: 1.454 billion yuan, 2027E: 1.618 billion yuan, and 2028E: 1.802 billion yuan [2]. - The earnings per share (EPS) are projected to be 6.47 yuan for 2024A, 4.27 yuan for 2025A, 4.80 yuan for 2026E, 5.34 yuan for 2027E, and 5.96 yuan for 2028E [2]. Operational Analysis - The company's gross margin for 2025 was reported at 92.7%, a decrease of 1.94 percentage points from the previous year [8]. - The sales expense ratio, management expense ratio, and R&D expense ratio for 2025 were 15.77%, 7.44%, and 14.67%, respectively, indicating an increase in overall expenses [8]. - The company is expanding its product matrix and therapeutic areas, with new product launches expected to contribute to future growth [9]. Strategic Outlook - The company is enhancing its international presence through acquisitions, such as the purchase of REGEN, which adds new products to its portfolio and strengthens its distribution channels [9]. - The report emphasizes the importance of monitoring the approval progress of new products and the integration of overseas operations as key factors for future growth [9].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has a rich pipeline reserve that lays the foundation for growth, with a focus on product sales progress [1] - The company is expected to achieve a net profit of 1.423 billion yuan in 2026, corresponding to a PE ratio of 27.4 times [7] - The company is pursuing a dual strategy of "R&D + M&A" to drive growth, with a strong emphasis on new product approvals and international business integration [7] Financial Performance Summary - For 2025, the company reported revenue of 2.453 billion yuan, a decrease of 18.9% year-on-year, and a net profit of 1.291 billion yuan, down 34.1% [7] - The core product revenue saw a decline, with solution-type injection products generating 1.265 billion yuan (down 27.5%) and gel-type injection products generating 890 million yuan (down 26.8%) [7] - The company has a comprehensive gross profit margin of 92.7% for 2025, which is a decrease of 1.9 percentage points [7] Earnings Forecast - Projected revenues for the years 2024 to 2028 are as follows: 3.026 billion yuan (2024), 2.453 billion yuan (2025), 2.775 billion yuan (2026), 3.058 billion yuan (2027), and 3.116 billion yuan (2028) [6] - The expected net profit for the years 2026 to 2028 is 1.423 billion yuan (2026), 1.582 billion yuan (2027), and 1.635 billion yuan (2028) [7] - The company’s return on equity (ROE) is projected to be 17.1% in 2026, decreasing to 16.3% by 2028 [6] Product Pipeline and Strategic Initiatives - The company has a robust pipeline with 12 Class III medical device product registrations, including the recently approved botulinum toxin type A and minoxidil solution [7] - The launch of the new product "Kakola" in May 2025 aims to enhance the product portfolio in facial contouring treatments [7] - The company has made strategic acquisitions, including REGEN in South Korea, to deepen its international strategy and enhance its regenerative product matrix [7]

Recent Events - The arbitration case between the company's subsidiary REGEN and Datoo regarding the agency rights for the AestheFill product is still under review. On January 30, 2026, the Shenzhen International Arbitration Court revoked the previous temporary sales restriction on REGEN, but the final outcome of the case has not yet been announced, which may impact the company's future business layout [2]. Business Development - The company is accelerating its diversification efforts, with the anti-hair loss product Minoxidil having obtained a drug registration certificate and is advancing in market promotion. The bone structure beauty filler product "Gekela" has received positive market feedback. These new products may become future growth points, although specific sales targets have not been publicly disclosed [3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.865 billion yuan and a net profit attributable to shareholders of 1.093 billion yuan, representing year-on-year declines of 21.49% and 31.05%, respectively. The gross profit margin remains high at 93.36%. The ongoing pressure on performance is attributed to intensified industry competition [4]. Stock and Capital Performance - Recent stock price fluctuations have been significant, with two large block trades occurring on February 3, 2026, at a transaction price of 113 yuan per share, reflecting a discount of 23.43%. On February 5, the stock price increased by 5.09% to 155.87 yuan per share. The flow of funds and changes in institutional holdings may reflect market sentiment [5].

Core Viewpoint - Recently, Aimeike (300896) announced that its subsidiary REGEN received a decision from the Shenzhen International Arbitration Court, which ruled not to implement the temporary measures previously ordered by an emergency arbitrator on September 10, 2025 [1] Group 1 - On September 10, 2025, the emergency arbitrator of the Shenzhen International Arbitration Court had issued a decision that restricted REGEN Biotech, Inc. from selling AestheFill products in China before the arbitration ruling was made [1] - The court's decision also stated that REGEN must acknowledge that Datuo Medical Devices (Shanghai) Co., Ltd. is the exclusive distributor of AestheFill products in China and must continue to supply the products to Datuo as per the agreement [1]

Core Viewpoint - The recent arbitration decision allows REGEN, a subsidiary of Aimeike, to sell AestheFill products in mainland China, but this is not a final ruling, and the ongoing dispute over distribution rights remains uncertain [2][8][20]. Group 1: Arbitration and Market Impact - Aimeike's subsidiary REGEN received a procedural decision from the Shenzhen International Arbitration Court, lifting a temporary measure that previously restricted its sales of AestheFill products in mainland China [2][8]. - Since the initial temporary measure was imposed on September 10, 2025, Aimeike's stock price has dropped nearly 30% [3]. - The arbitration dispute began after Aimeike acquired 85% of REGEN for $190 million in March 2025, leading to REGEN unilaterally terminating its exclusive distribution agreement with Dato Medical [6][8]. Group 2: Business Performance - Aimeike has faced a decline in revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues of 663 million, 636 million, and 566 million yuan, representing year-on-year declines of 17.90%, 25.11%, and 21.27% respectively [11]. - The decline in revenue is attributed to a weakened consumer confidence due to macroeconomic conditions and increased competition in the medical aesthetics industry [14][15]. - Aimeike's main revenue sources, solution and gel injection products, saw significant revenue drops, with total income from these products falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 [15][16]. Group 3: Future Outlook - The AestheFill product, despite its potential, is expected to contribute only around 300 million yuan in annual sales, which may not significantly offset the revenue decline from Aimeike's core products [17]. - The competitive landscape for botulinum toxin products is also challenging, with established players dominating the market, making it difficult for Aimeike to gain market share with newly approved products [18]. - Overall, Aimeike is likely to continue facing significant performance pressures into 2026, despite the short-term positive impact of the arbitration decision [19][20].

Core Viewpoint - The arbitration decision to lift the temporary sales restriction on AestheFill products by REGEN, a subsidiary of Aimeike, is seen as a short-term positive development, but the underlying dispute over distribution rights remains unresolved, indicating potential volatility in the company's stock performance [1][4][14]. Group 1: Arbitration and Sales Rights - REGEN received a decision from the Shenzhen International Arbitration Court on January 29, 2025, which lifted a temporary measure that prohibited the sale of AestheFill products in mainland China [1]. - The temporary measure was initially imposed following REGEN's unilateral termination of its exclusive distribution agreement with Dato Medical, which claimed that Dato had transferred its distribution rights to a related party, violating the agreement [3][4]. - The arbitration decision is procedural and not a final ruling, meaning the dispute over the legality of REGEN's termination of the distribution rights is still ongoing [4]. Group 2: Financial Performance - Aimeike has experienced a decline in both revenue and profit for four consecutive quarters, with Q1-Q3 2025 revenues reported at 663 million, 636 million, and 566 million yuan, reflecting year-on-year decreases of 17.90%, 25.11%, and 21.27% respectively [5][6]. - The company's core products, including solution and gel injection products, saw significant revenue drops, with total income from these categories falling from 9.76 billion yuan in 2024 to 7.44 billion yuan in 2025 for solution products, and from 6.49 billion yuan to 4.93 billion yuan for gel products [9][10]. - The competitive landscape has intensified, with new entrants in the aesthetic medicine market impacting Aimeike's profit margins and market share [8][9]. Group 3: Future Outlook - The introduction of AestheFill is expected to provide some revenue support, but its annual sales of approximately 300 million yuan may not be sufficient to offset the significant revenue declines from Aimeike's core products [10][11]. - The company faces challenges in gaining market share for newly approved products, such as botulinum toxin, due to established competitors dominating the market [12][13]. - Overall, Aimeike is likely to continue facing substantial performance pressures into 2026, with the recent arbitration decision providing only a temporary boost [14].